S-1: BioVie Inc. Files S-1 for Public Offering of Units and Warrants Amidst Clinical Trial Progress and Nasdaq Delisting Concerns

BioVie Inc. has filed a registration statement for a public offering of units and pre-funded units, aiming to raise capital for its clinical-stage drug development programs while facing significant dilution and potential Nasdaq delisting risks.

Summary

• BioVie Inc. is offering 1,456,310 units, each consisting of one share of Class A Common Stock and one warrant to purchase one share of Common Stock, at an assumed public offering price of $10.30 per unit.
• The company is also offering 1,456,310 pre-funded units, each comprising one pre-funded warrant to purchase one share of Common Stock and one warrant, priced at the unit price minus $0.0001, primarily for purchasers who would otherwise exceed beneficial ownership limits.
• Each warrant will entitle the holder to purchase one share of Common Stock at an exercise price of $12.875 and will expire five years from the issuance date.
• The pre-funded warrants are immediately exercisable at a nominal exercise price of $0.0001 per share and do not expire until fully exercised.
• The offering is expected to generate approximately $13.5 million in net proceeds, or $15.6 million if the underwriters' over-allotment option is fully exercised, intended for working capital and general corporate purposes.
• The company's shares of Common Stock are listed on Nasdaq under the symbol BIVI, and it intends to apply to list the Warrants on Nasdaq under the symbol BIVIW, though listing is not guaranteed.
• A 1-for-10 reverse stock split was approved by stockholders on June 23, 2025, and by the Board on June 26, 2025, becoming effective on July 7, 2025.
• BioVie is a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) with bezisterim (NE3107) and advanced liver disease (ascites) with BIV201.
• The Phase 3 clinical trial for bezisterim in mild-to-moderate Alzheimer's disease (NCT04669028) was underpowered due to significant protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and referral to the FDA Office of Scientific Investigations.
• A Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) showed significant improvements in morning 'on' symptoms and motor control when combined with levodopa, with no drug-related adverse events.
• The company received a $13.1 million grant from the U.S. Department of Defense in April 2024 to fund the Phase 2 ADDRESS-LC study of bezisterim for neurological symptoms associated with Long COVID, which commenced in May 2025.
• BIV201 (continuous infusion terlipressin) for advanced liver cirrhosis complications has FDA Fast Track and Orphan Drug designations, and a Phase 2 study (NCT04112199) showed a 53% reduction in ascites fluid in treated patients.
• The company is finalizing the protocol design for a Phase 3 study of BIV201 targeting a broader ascites patient population, focusing on a composite primary endpoint of complications and disease progression in patients recovering from acute kidney injury (AKI).

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant dilution, the explicit risk of Nasdaq delisting, and serious issues with the Phase 3 Alzheimer's trial (cGCP violations, underpowered). While there are positive clinical developments in other areas and grant funding, the immediate financial and operational risks highlighted in the filing outweigh these positives for overall sentiment.

Positives

• BioVie's drug candidate bezisterim (NE3107) is an orally bioavailable, Blood Brain Barrier (BBB)-permeable, insulin-sensitizer and anti-inflammatory agent with a low risk of drug-drug interaction.
• Positive Phase 2 investigator-initiated trial data for bezisterim in Alzheimer's disease (NCT05227820) showed improved cognition and biomarker levels.
• Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) demonstrated significant improvements in morning 'on' symptoms and clinically meaningful improvement in motor control, with no drug-related adverse events.
• Bezisterim has the potential to reduce neurological symptoms, including fatigue and cognitive dysfunction, in Long COVID patients.
• The company was awarded a $13.1 million clinical trial grant from the U.S. Department of Defense (DOD) in April 2024 to fully fund the Phase 2 ADDRESS-LC study for Long COVID.
• BIV201 (continuous infusion terlipressin) received both FDA Fast Track designation status and FDA Orphan Drug Status for ascites.
• A Phase 2 study of BIV201 for refractory ascites showed a 53% reduction in ascites fluid in treated patients, sustained for three months after treatment initiation.
• BIV201 features a novel room-temperature stable liquid formulation in a pre-filled syringe, offering potential product differentiation and convenience compared to existing terlipressin products that require refrigeration.
• Patents for BIV201's novel liquid formulation have been granted in the U.S., China, Japan, Chile, and India.

Negatives

• The Phase 3 clinical trial for bezisterim in Alzheimer's disease (NCT04669028) was significantly underpowered for its primary endpoints due to the exclusion of patients from 15 study sites that exhibited significant protocol deviations and cGCP violations.
• The company referred the problematic AD study sites to the FDA Office of Scientific Investigations (OSI) for potential further action, indicating serious issues with data integrity.
• The public offering price per Unit may be at a significant discount to the assumed offering price, and Nasdaq may seek to delist the Common Stock if the offering does not qualify as a public offering under its stockholder approval rule, especially if the discount is 50% or more.
• Investing in the Common Stock involves a high degree of risk, including immediate and substantial dilution in net tangible book value per share.
• The company does not intend to pay dividends on its Common Stock, meaning returns are limited to stock price appreciation, which may never occur.
• Future equity offerings or exercise of existing options and warrants could lead to further dilution for current stockholders.
• There is a limited trading market for the Common Stock, which could make it difficult to liquidate an investment, and no established trading market for the Pre-funded Warrants or Warrants is expected to develop.
• The company's management team has limited public company experience, which could adversely impact compliance with U.S. securities laws and reporting requirements.
• The company's independent registered public accounting firm's report includes an explanatory paragraph about substantial doubt concerning the company's ability to continue as a going concern.

Risks

• Immediate and substantial dilution in the net tangible book value per share for new investors.
• Management will have broad discretion over the use of net proceeds from the offering, which may not yield a significant return or align with investor expectations.
• The company's stock price is and may continue to be volatile, and shareholders may not be able to resell Common Stock at or above the purchase price.
• Risk of Nasdaq delisting if the offering does not qualify as a 'public offering' under Nasdaq's stockholder approval rule, particularly if securities are sold at a deep discount.
• No intention to pay dividends on Common Stock, limiting investor returns to stock price appreciation.
• Future dilution from additional equity offerings or exercise of outstanding options, warrants, and equity awards.
• Potential for downward adjustment of exercise prices for certain outstanding warrants (Acuitas Warrants) if future sales of convertible securities occur at a lower deemed issuance price.
• The company is obligated to issue up to 1.8 million shares of Common Stock upon achievement of certain clinical, regulatory, and commercial milestones for its drug candidates, further diluting existing stockholders.
• The existence of a limited trading market for Common Stock could hinder liquidity.
• No established public trading market for the Pre-funded Warrants or Warrants, limiting their liquidity and potentially reducing the trading volume and price of Common Stock.
• Warrants and Pre-funded Warrants are speculative in nature and may have no value in a bankruptcy or reorganization proceeding.
• Significant holders of Pre-funded Warrants may be limited in their ability to exercise due to beneficial ownership limitations (4.99% or 9.99% at election).
• The Reverse Stock Split could cause the stock price to decline relative to its pre-split value and decrease liquidity.
• Any failure to maintain effective internal control over financial reporting could harm the company and investor confidence.
• The lack of public company experience of the management team could adversely impact compliance with U.S. securities laws.
• As a smaller reporting company, the company is exempt from certain disclosure requirements, which could make its stock less attractive to potential investors.
• Ongoing audit and legal fees associated with periodic reporting requirements will negatively affect the company's ability to earn a profit.
• The company is authorized to issue blank check preferred stock without stockholder approval, which could adversely impact the rights of Common Stock holders and potentially deter changes in control.
• Provisions in the company's Articles of Incorporation, Bylaws, and Nevada law might discourage, delay, or prevent a change in control or management.

Future Outlook

BioVie Inc. plans to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, research and development, and acquisitions. The company is finalizing the protocol design for a Phase 3 study of BIV201 for ascites and is continuing its Phase 2b study of bezisterim for new onset Parkinson's disease and the Phase 2 ADDRESS-LC study for Long COVID.

Management Comments

• Management will have broad discretion over the use of proceeds from this offering, and investors are relying on their judgment.
• The company's management acknowledges that the calculation of beneficial ownership for exercise limitations is the sole responsibility of the holder, and the company has no obligation to verify or confirm its accuracy.

Industry Context

BioVie Inc. operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on developing novel drug therapies for neurological and neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company's strategy involves advancing its lead drug candidates, bezisterim and BIV201, through clinical trials to address significant unmet medical needs. The receipt of a DOD grant for Long COVID research and FDA Fast Track/Orphan Drug designations for BIV201 highlight recognition of the potential impact of its pipeline, but the industry is characterized by high R&D costs, lengthy regulatory processes, and high failure rates.

Corporate Governance

Legal Proceedings

• The company referred 15 study sites from its Phase 3 Alzheimer's clinical trial to the FDA Office of Scientific Investigations (OSI) due to significant deviation from protocol and current good clinical practices (cGCPs) violations.

Related Party Transactions

• The company acquired biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• BioVie is obligated to pay a low single-digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc., which will become a 5.0% royalty on net sales under a separation agreement.

Stakeholder Impact

• **Shareholders:** Face immediate and substantial dilution from the offering, potential stock price volatility, and the risk of Nasdaq delisting. Existing shareholders will see a decrease in net tangible book value per share. Future dilution from outstanding options, warrants, and milestone-based share issuances is also a concern.
• **Investors in the Offering:** Will experience immediate dilution and are subject to the risks of stock price volatility and potential delisting. The lack of an established trading market for warrants limits their liquidity.
• **Employees:** The company's financial health and ability to continue operations, including clinical trials, directly impact job security and future prospects. Management's limited public company experience could affect operational stability.
• **Customers (Future Patients):** The progress and success of clinical trials for bezisterim and BIV201 are crucial for bringing new therapies to market, potentially addressing significant unmet medical needs in neurological disorders and liver disease.
• **Creditors:** The company's ability to continue as a going concern, as noted by its auditor, is a risk factor for creditors, although the capital raise aims to improve liquidity.

Next Steps

• Finalize the protocol design for the Phase 3 study of BIV201 for cirrhosis and ascites, focusing on a composite primary endpoint.
• Continue the Phase 2b study of bezisterim as a potential first-line therapy for new onset Parkinson's disease.
• Continue the Phase 2 ADDRESS-LC study of bezisterim for neurological symptoms associated with Long COVID.
• Maintain listing of Common Stock and seek listing for Warrants on Nasdaq.
• Comply with all applicable provisions of the Sarbanes-Oxley Act and maintain effective internal controls over financial reporting.

Key Dates

Recommendation

Keywords

BioVie Inc., BIVI, SEC Filing, S-1 Registration Statement, Public Offering, Units Offering, Pre-Funded Warrants, Common Stock, Warrants, Biopharmaceutical, Clinical Stage, Neurodegenerative Disorders, Alzheimer's Disease, Parkinson's Disease, Long COVID, Bezisterim, NE3107, Liver Cirrhosis, Ascites, BIV201, Terlipressin, FDA Fast Track, Orphan Drug Designation, Clinical Trials, Phase 2 Study, Phase 3 Study, Reverse Stock Split, Dilution, Nasdaq Listing, Capital Raise, Risk Factors, Corporate Governance, Financial Reporting